MedTrace Logo

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

NCT00674700 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 509

Last updated 2016-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily over a period of 12 months compared to placebo, for reduction of allergic rhinitis symptoms and rescue medication usage

Conditions

  • Allergic Rhinitis

Interventions

DRUG

300 IR house dust mites allergen extract tablet

One sublingual tablet daily for one year

DRUG

500 IR house dust mites allergen extract tablet

One sublingual tablet daily for one year

DRUG

Placebo tablet

One sublingual tablet daily for one year

Sponsors & Collaborators

  • Stallergenes Greer

    lead INDUSTRY

Principal Investigators

  • Karl-Christian BERGMANN, MD · Allergie-Centrum-Charité / ECARF

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-02-28
Completion
2010-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674700 on ClinicalTrials.gov